Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure
Open Access
- 13 May 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 29 (20), 2506-2513
- https://doi.org/10.1093/eurheartj/ehn360
Abstract
To investigate the association of arginine methylation with myocardial function and prognosis in chronic systolic heart failure patients. Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), as well as N-mono-methylarginine (MMA) and methyl-lysine, were simultaneously measured by tandem mass spectrometry in 132 patients with chronic systolic heart failure with echocardiographic evaluation and follow-up. Increasing ADMA and SDMA levels were associated with elevated natriuretic peptide levels (both P < 0.001), and increasing SDMA levels were associated with worsening renal function (P < 0.001). Higher plasma levels of methylated arginine metabolites (but not methyl-lysine) were associated with the presence of left ventricular (LV) diastolic dysfunction (E/septal E′, Spearman's r = 0.31–0.36, P < 0.001). Patients taking beta-blockers had lower ADMA levels than those not taking beta-blockers [0.42 (0.33, 0.50) vs. 0.51 (0.40, 0.58), P < 0.001]. Only increasing ADMA levels were associated with advanced right ventricular (RV) systolic dysfunction. Elevated ADMA levels remained a consistent independent predictor of adverse clinical events (hazard ratio = 1.64, 95% CI: 1.20–2.22, P = 0.002). In chronic systolic heart failure, accumulation of methylated arginine metabolites is associated with the presence of LV diastolic dysfunction. Among the methylated derivatives of arginine, ADMA provides the strongest independent prediction of disease progression and adverse long-term outcomes.Keywords
This publication has 30 references indexed in Scilit:
- Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial InfarctionCirculation, 2007
- Asymmetric Dimethylarginine Enhances Cardiovascular Risk Prediction in Patients With Chronic Heart FailureArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Asymmetric Dimethylarginine Predicts Cardiovascular Events in Patients With Type 2 DiabetesDiabetes Care, 2007
- Asymmetrical Dimethylarginine Independently Predicts Total and Cardiovascular Mortality in Individuals with Angiographic Coronary Artery Disease (The Ludwigshafen Risk and Cardiovascular Health Study)Clinical Chemistry, 2007
- Carvedilol improves endothelium-dependent vasodilation in patients with dilated cardiomyopathyHeart, 2005
- Dimethylarginine dimethylaminohydrolase and endothelial dysfunction in failing heartsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Nitric oxide's role in the heart: control of beating or breathing?American Journal of Physiology-Heart and Circulatory Physiology, 2004
- Cardiovascular Biology of the Asymmetric Dimethylarginine:Dimethylarginine Dimethylaminohydrolase PathwayArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Asymmetric Dimethylarginine Causes Hypertension and Cardiac Dysfunction in Humans and Is Actively Metabolized by Dimethylarginine DimethylaminohydrolaseArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Early Induction of Transforming Growth Factor-β via Angiotensin II Type 1 Receptors Contributes to Cardiac Fibrosis Induced by Long-term Blockade of Nitric Oxide Synthesis in RatsHypertension, 1998